{"id":"W4226329559","doi":"10.3390/curroncol29050247","title":"Immune Checkpoint Inhibitors in Cancer Therapy","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1280,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Nivolumab; Durvalumab; Medicine; Ipilimumab; Avelumab; Pembrolizumab; Atezolizumab; Immunotherapy; CTLA-4; Immune checkpoint; Cancer; Cancer immunotherapy; Lung cancer; Oncology; Immunology; Immune system; Cancer research; Internal medicine; T cell","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005044064,0.0005856608,0.0008591261,0.001612025,0.0001812338,0.0007866113,0.0005885148,0.0008071055,0.00483101],"category_scores_gemma":[0.0006391259,0.000167666,0.0005441622,0.001246211,0.0002720924,0.00086061,0.0005569904,0.001954841,0.002173451],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00053248,"about_ca_system_score_gemma":0.0008293194,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005763964,"about_ca_topic_score_gemma":0.001364203,"domain_scores_codex":[0.9997826,0.0000460479,0.00002860084,0.00003016044,0.00008973716,0.00002289087],"domain_scores_gemma":[0.9997544,0.0001115347,0.00003831234,0.000007903846,0.0000682529,0.00001960457],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007402608,0.00006620946,0.0001297133,0.011872,0.00008755583,0.0001124969,0.00003398917,0.0002631831,0.001178121,0.003053652,0.03769585,0.9454331],"study_design_scores_gemma":[0.00002397445,0.00007358281,0.0004024827,0.003387753,0.0000770055,0.0006939074,0.00001976168,0.00006908933,0.000301216,0.001398767,0.9935439,0.000008584225],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000115009,0.9978361,0.00009520036,0.0004058944,0.000310917,0.000006969622,0.00002070991,0.00000848344,0.001200733],"genre_scores_gemma":[0.0009176098,0.9971921,0.0001793948,0.0003990362,0.0002717332,0.000009095226,0.00004352222,0.000001691839,0.0009857801],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00483101,"threshold_uncertainty_score":0.01616138,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2411030219700868,"score_gpt":0.483593654542637,"score_spread":0.2424906325725502,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}